ERBB2 and adenocarcinoma: Additionally, the analysis suggests that the cost of cadonilimab (125 mg) must be reduced to below 54.89% of its current price—specifically, under $129.50—for CAD-CHM to become a cost-effective first-line option for HER2-negative advanced G/GEJ adenocarcinoma in the overall population.